Safwat AS, et al. - In patients with benign prostatic hyperplasia (BPH), authors sought to evaluate how cholecalciferol could be used for prophylaxis against recurrent urinary tract infection (UTI). They randomly allocated patients to either group-A (193 patients) who received tamsulosin, or group-B (196 patients) who received tamsulosin with cholecalciferol. Among patients with BPH receiving tamsulosin therapy, adjuvant cholecalciferol supplementation seems to be protective against recurrent UTI without extra adverse effects. Among the study population, the incidence rate of recurrent UTI was 9%. Compared to group-B patients, the incidence rate was significantly higher among group-A patients.